Last reviewed 2026-04-23 · How we verify

Placebo SC Q4W

This is a placebo control used in clinical trials and does not exert any active pharmacological effect.

At a glance

Mechanism of action

Placebo is an inert substance administered in controlled clinical studies to serve as a comparator arm against the active investigational drug. It allows researchers to isolate the true therapeutic effect of the active agent by controlling for natural disease progression, regression to the mean, and patient expectation effects.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (PHASE2, PHASE3)
• Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP (PHASE3)
• Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS (PHASE3)
• A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) (PHASE3)
• A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) (PHASE3)
• A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD) (PHASE2)
• A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy (PHASE2)
• An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.